|
1
|
Trautmann L, Said EA, Halwani R, Janbazian
L, Chomont N, El-Far M, Breton G, Haddad EK and Sekaly RP:
Programmed death 1: A critical regulator of T-cell function and a
strong target for immunotherapies for chronic viral infections.
Curr Opin HIV AIDS. 2:219–227. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tanzarella S, Lionello I, Valentinis B,
Russo V, Lollini PL and Traversari C: Rhabdomyosarcomas are
potential target of MAGE-specific immunotherapies. Cancer Immunol
Immunother. 53:519–524. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Selvan SR, Dowling JP, Kelly WK and Lin J:
Indoleamine 2,3-dioxygenase (IDO): Biology and target in cancer
immunotherapies. Curr Cancer Drug Targets. 16:755–764. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pier GB: Rationale for development of
immunotherapies that target mucoid Pseudomonas aeruginosa infection
in cystic fibrosis patients. Behring Inst Mitt. 1–360. 1997.
|
|
5
|
Cafarotti S, Lococo F, Froesh P, Zappa F
and Andrè D: Target therapy in lung cancer. Adv Exp Med Biol.
893:127–136. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Magnuson WJ, Yeung JT, Guillod PD,
Gettinger SN, Yu JB and Chiang VL: Impact of deferring radiation
therapy in patients with epidermal growth factor receptor-mutant
non-small cell lung cancer who develop brain metastases. Int J
Radiat Oncol Biol Phys. 95:673–679. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhukovsky M, Varaksin A and Pakholkina O:
Statistical analysis of observational study of the influence of
radon and other risk factors on lung cancer incidence. Radiat Prot
Dosimetry. 160:108–111. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brody H: Lung cancer. Nature. 513
Suppl:S12014. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moro-Sibilot D, Smit E, de Castro Carpeño
J, Lesniewski-Kmak K, Aerts JG, Villatoro R, Kraaij K, Nacerddine
K, Dyachkova Y, Smith KT, et al: Non-small cell lung cancer
patients with brain metastases treated with first-line
platinum-doublet chemotherapy: Analysis from the European FRAME
study. Lung Cancer. 90:427–432. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Barnett SA, Downey RJ, Zheng J, Plourde G,
Shen R, Chaft J, Akhurst T, Park BJ and Rusch VW: Utility of
routine PET imaging to predict response and survival after
induction therapy for non-small cell lung cancer. Ann Thorac Surg.
101:1052–1059. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xie FJ, Lu HY, Zheng QQ, Qin J, Gao Y,
Zhang YP, Hu X and Mao WM: The clinical pathological
characteristics and prognosis of FGFR1 gene amplification in
non-small-cell lung cancer: A meta-analysis. Onco Targets Ther.
9:171–181. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lim SH, Sun JM, Lee SH, Ahn JS, Park K and
Ahn MJ: Pembrolizumab for the treatment of non-small cell lung
cancer. Expert Opin Biol Ther. 16:397–406. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lupo B, Vialard J, Sassi F, Angibaud P,
Puliafito A, Pupo E, Lanzetti L, Comoglio PM, Bertotti A and
Trusolino L: Tankyrase inhibition impairs directional migration and
invasion of lung cancer cells by affecting microtubule dynamics and
polarity signals. BMC Biol. 14:52016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Müller B, Bovet M, Yin Y, Stichel D, Malz
M, González-Vallinas M, Middleton A, Ehemann V, Schmitt J, Muley T,
et al: Concomitant expression of far upstream element (FUSE)
binding protein (FBP) interacting repressor (FIR) and its splice
variants induce migration and invasion of non-small cell lung
cancer (NSCLC) cells. J Pathol. 237:390–401. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao Q, Yue J, Zhang C, Gu X, Chen H and
Xu L: Inactivation of M2 AChR/NF-κB signaling axis reverses
epithelial-mesenchymal transition (EMT) and suppresses migration
and invasion in non-small cell lung cancer (NSCLC). Oncotarget.
6:29335–29346. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang H, Zhu X, Li N, Li D, Sha Z, Zheng X
and Wang H: miR-125a-3p targets MTA1 to suppress NSCLC cell
proliferation, migration, and invasion. Acta Biochim Biophys Sin
(Shanghai). 47:496–503. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Roth MT, Ivey JL, Esserman DA, Crisp G,
Kurz J and Weinberger M: Individualized medication assessment and
planning: Optimizing medication use in older adults in the primary
care setting. Pharmacotherapy. 33:787–797. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shukla VC, Higuita-Castro N, Nana-Sinkam P
and Ghadiali SN: Substrate stiffness modulates lung cancer cell
migration but not epithelial to mesenchymal transition. J Biomed
Mater Res A. 104:1182–1193. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shirahata A, Fan W, Sakuraba K, Yokomizo
K, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, et
al: MACC 1 as a marker for vascular invasive hepatocellular
carcinoma. Anticancer Res. 31:777–780. 2011.PubMed/NCBI
|
|
20
|
Shirahata A, Sakata M, Kitamura Y,
Sakuraba K, Yokomizo K, Goto T, Mizukami H, Saito M, Ishibashi K,
Kigawa G, et al: MACC 1 as a marker for peritoneal-disseminated
gastric carcinoma. Anticancer Res. 30:3441–3444. 2010.PubMed/NCBI
|
|
21
|
Bai F, Tian H, Niu Z, Liu M, Ren G, Yu Y,
Sun T, Li S and Li D: Chimeric anti-IL-17 full-length monoclonal
antibody is a novel potential candidate for the treatment of
rheumatoid arthritis. Int J Mol Med. 33:711–721. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lanyon SR and Reichel MP: Pretreatment of
serum samples to reduce interference of colostrum-derived specific
antibodies with detection of Bovine viral diarrhea virus antigen by
ELISA in young calves. J Vet Diagn Invest. 28:345–349. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Trino S, Iacobucci I, Erriquez D,
Laurenzana I, De Luca L, Ferrari A, Di Rorà A Ghelli Luserna,
Papayannidis C, Derenzini E, Simonetti G, et al: Targeting the
p53-MDM2 interaction by the small-molecule MDM2 antagonist
Nutlin-3a: A new challenged target therapy in adult Philadelphia
positive acute lymphoblastic leukemia patients. Oncotarget.
7:12951–12961. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma J, Ma J, Meng Q, Zhao ZS and Xu WJ:
Prognostic value and clinical pathology of MACC-1 and c-MET
expression in gastric carcinoma. Pathol Oncol Res. 19:821–832.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-tie quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhuang T, Djemil T, Qi P, Magnelli A,
Stephans K, Videtic G and Xia P: Dose calculation differences
between Monte Carlo and pencil beam depend on the tumor locations
and volumes for lung stereotactic body radiation therapy. J Appl
Clin Med Phys. 14:40112013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang L, Lin L, Chen X, Sun L, Liao Y,
Huang N and Liao W: Metastasis-associated in colon cancer-1
promotes vasculogenic mimicry in gastric cancer by upregulating
TWIST1/2. Oncotarget. 6:11492–11506. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee YT, Liu CJ, Hu YW, Teng CJ, Tzeng CH,
Yeh CM, Chen TJ, Lin JK, Lin CC, Lan YT, et al: Incidence of second
primary malignancies following colorectal cancer: A distinct
pattern of occurrence between colon and rectal cancers and
association of Co-morbidity with second primary malignancies in a
population-based cohort of 98,876 patients in Taiwan. Medicine
(Baltimore). 94:e10792015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim DS, Park KM, Won YS, Kim JY, Lee JK,
Kim JG, Oh ST, Jung SS and Kang WK: Occurrence and prognosis of
symptomatic venous thromboembolism in colorectal cancer surgery
patients. Vasc Specialist Int. 30:49–55. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wink KC, Belderbos JS, Dieleman EM, Rossi
M, Rasch CR, Damhuis RA, Houben RM and Troost EG: Improved
progression free survival for patients with diabetes and locally
advanced non-small cell lung cancer (NSCLC) using metformin during
concurrent chemoradiotherapy. Radiother Oncol. 118:453–459. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Charvat H, Sasazuki S, Inoue M, Iwasaki M,
Sawada N, Shimazu T, Yamaji T and Tsugane S: JPHC Study Group:
Prediction of the 10-year probability of gastric cancer occurrence
in the Japanese population: The JPHC study cohort II. Int J Cancer.
138:320–331. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gold M, Dunn LB, Phoenix B, Paul SM,
Hamolsky D, Levine JD and Miaskowski C: Co-occurrence of anxiety
and depressive symptoms following breast cancer surgery and its
impact on quality of life. Eur J Oncol Nurs. 20:97–105. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Arora S, Ranade AR, Tran NL, Nasser S,
Sridhar S, Korn RL, Ross JT, Dhruv H, Foss KM, Sibenaller Z, et al:
MicroRNA-328 is associated with (non-small) cell lung cancer
(NSCLC) brain metastasis and mediates NSCLC migration. Int J
Cancer. 129:2621–2631. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Han L, Liang XH, Chen LX, Bao SM and Yan
ZQ: SIRT1 is highly expressed in brain metastasis tissues of
non-small cell lung cancer (NSCLC) and in positive regulation of
NSCLC cell migration. Int J Clin Exp Pathol. 6:2357–2365.
2013.PubMed/NCBI
|
|
35
|
Sun L, Duan J, Jiang Y, Wang L, Huang N,
Lin L, Liao Y and Liao W: Metastasis-associated in colon cancer-1
upregulates vascular endothelial growth factor-C/D to promote
lymphangiogenesis in human gastric cancer. Cancer Lett.
357:242–253. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lederer A, Herrmann P, Seehofer D, Dietel
M, Pratschke J, Schlag P and Stein U: Metastasis-associated in
colon cancer 1 is an independent prognostic biomarker for survival
in Klatskin tumor patients. Hepatology. 62:841–850. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Stein U, Walther W, Arlt F, Schwabe H,
Smith J, Fichtner I, Birchmeier W and Schlag PM: MACC1, a newly
identified key regulator of HGF-MET signaling, predicts colon
cancer metastasis. Nat Med. 15:59–67. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Boardman LA: Overexpression of MACC1 leads
to downstream activation of HGF/MET and potentiates metastasis and
recurrence of colorectal cancer. Genome Med. 1:362009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shimokawa H, Uramoto H, Onitsuka T,
Chundong G, Hanagiri T, Oyama T and Yasumoto K: Overexpression of
MACC1 mRNA in lung adenocarcinoma is associated with postoperative
recurrence. J Thorac Cardiovasc Surg. 141:895–898. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Migliore C, Martin V, Leoni VP, Restivo A,
Atzori L, Petrelli A, Isella C, Zorcolo L, Sarotto I, Casula G, et
al: miR-1 downregulation cooperates with MACC1 in promoting MET
overexpression in human colon cancer. Clin Cancer Res. 18:737–747.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang T, Kong B, Kuang YQ, Cheng L, Gu JW,
Zhang JH, Shu HF, Yu SX, He WQ, Xing XM and Huang HD:
Overexpression of MACC1 protein and its clinical implications in
patients with glioma. Tumour Biol. 35:815–819. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang Z, Li Z, Wu C, Wang Y, Xia Y, Chen L,
Zhu Q and Chen Y: MACC1 overexpression predicts a poor prognosis
for non-small cell lung cancer. Med Oncol. 31:7902014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang G, Fu Z and Li D: MACC1
overexpression and survival in solid tumors: A meta-analysis.
Tumour Biol. 36:1055–1065. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li H, Zhang H, Zhao S, Shi Y, Yao J, Zhang
Y, Guo H and Liu X: Overexpression of MACC1 and the association
with hepatocyte growth factor/c-Met in epithelial ovarian cancer.
Oncol Lett. 9:1989–1996. 2015.PubMed/NCBI
|
|
45
|
Nakamura K, Nozawa K, Aoyagi Y, Ishihara
S, Matsuda K, Fukushima J and Watanabe T: A case report of thyroid
gland metastasis associated with lung metastasis from colon cancer.
Tumori. 97:229–232. 2011.PubMed/NCBI
|
